Although much attention is currently focused on the weight management potential of incretin-based medications, such as glucagon-like peptide-1 (GLP-1) receptor agonists, there is also a growing focus on the effects in patients with chronic kidney disease (CKD). The US Food and Drug Administration approved the GLP-1 receptor agonist semaglutide to reduce kidney and cardiovascular risk in patients with type 2 diabetes and CKD in January 2025, with data on treatment effects still accumulating. In this issue of AJKD, Chen et al1 present a meta-analysis of kidney and cardiovascular outcomes among patients with CKD (estimated glomerular filtration rate [eGFR]